Gilead Announces 96-Week Results From Phase 3 Study of Biktarvy® (Bictegravir, Emtricitabine, Tenofovir Alafenamide) for the Treatment of HIV-1 in Adults New to HIV Therapy
FOSTER CITY, Calif.–(BUSINESS WIRE)– – Biktarvy Showed High Efficacy and a Demonstrated Tolerability Profile Through 96 Weeks – Gilead Sciences, Inc. (Nasdaq: GILD) today announced...